ChemoCentryx, Inc. (CCXI) Cut to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of ChemoCentryx, Inc. (NASDAQ:CCXI) from a buy rating to a hold rating in a research note issued to investors on Monday morning.

According to Zacks, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. “

A number of other research analysts have also recently issued reports on CCXI. Cowen and Company reissued a hold rating on shares of ChemoCentryx in a research note on Tuesday, August 8th. BidaskClub cut ChemoCentryx from a strong-buy rating to a buy rating in a research note on Thursday, August 10th. Finally, ValuEngine cut ChemoCentryx from a hold rating to a sell rating in a research note on Saturday, October 21st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $8.25.

Shares of ChemoCentryx (NASDAQ:CCXI) opened at $7.26 on Monday. ChemoCentryx has a 52 week low of $6.13 and a 52 week high of $10.80.

ChemoCentryx (NASDAQ:CCXI) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. equities research analysts anticipate that ChemoCentryx will post -0.67 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at

Institutional investors have recently modified their holdings of the company. Bank of Montreal Can bought a new stake in ChemoCentryx during the second quarter worth about $102,000. JPMorgan Chase & Co. bought a new stake in ChemoCentryx during the second quarter worth about $104,000. Voya Investment Management LLC raised its holdings in ChemoCentryx by 22.8% during the second quarter. Voya Investment Management LLC now owns 15,984 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 2,965 shares in the last quarter. Trexquant Investment LP raised its stake in ChemoCentryx by 81.1% in the second quarter. Trexquant Investment LP now owns 18,600 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 8,327 shares during the period. Finally, State of Wisconsin Investment Board bought a new stake in ChemoCentryx in the second quarter valued at approximately $178,000. Institutional investors own 49.15% of the company’s stock.

About ChemoCentryx

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Get a free copy of the Zacks research report on ChemoCentryx (CCXI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply